Titration schedule planner
GLP-1 Titration Schedule Planner
Generate a personalized week-by-week titration calendar for any GLP-1 medication using the exact dose-escalation schedule from each drug's FDA Prescribing Information. Select your medication, choose a start date, and optionally indicate your current dose to see only the remaining schedule.
Important: Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol — do not change doses without medical guidance. If side effects are intolerable at any step, contact your prescriber before the next increase.
Wegovy (semaglutide 2.4 mg) — titration calendar
| Week | Date range | Dose | Pen color | Notes |
|---|---|---|---|---|
| 1 | May 30, 2026 — Jun 5, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 2 | Jun 6, 2026 — Jun 12, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 3 | Jun 13, 2026 — Jun 19, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 4 | Jun 20, 2026 — Jun 26, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 5 | Jun 27, 2026 — Jul 3, 2026 | 0.5 mg weekly | Red-violet | |
| 6 | Jul 4, 2026 — Jul 10, 2026 | 0.5 mg weekly | Red-violet | |
| 7 | Jul 11, 2026 — Jul 17, 2026 | 0.5 mg weekly | Red-violet | |
| 8 | Jul 18, 2026 — Jul 24, 2026 | 0.5 mg weekly | Red-violet | |
| 9 | Jul 25, 2026 — Jul 31, 2026 | 1 mg weekly | Yellow | |
| 10 | Aug 1, 2026 — Aug 7, 2026 | 1 mg weekly | Yellow | |
| 11 | Aug 8, 2026 — Aug 14, 2026 | 1 mg weekly | Yellow | |
| 12 | Aug 15, 2026 — Aug 21, 2026 | 1 mg weekly | Yellow | |
| 13 | Aug 22, 2026 — Aug 28, 2026 | 1.7 mg weekly | Teal | |
| 14 | Aug 29, 2026 — Sep 4, 2026 | 1.7 mg weekly | Teal | |
| 15 | Sep 5, 2026 — Sep 11, 2026 | 1.7 mg weekly | Teal | |
| 16 | Sep 12, 2026 — Sep 18, 2026 | 1.7 mg weekly | Teal | |
| 17 | Sep 19, 2026 — Sep 25, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 18 | Sep 26, 2026 — Oct 2, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 19 | Oct 3, 2026 — Oct 9, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 20 | Oct 10, 2026 — Oct 16, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
How the planner works
Every dose, duration, and pen color in this planner comes directly from the FDA Prescribing Information (PI) for each medication. The planner does not invent or modify doses — it generates a calendar view of the exact FDA-label protocol.
- Wegovy (semaglutide) [1]: 16-week titration from 0.25 mg to 2.4 mg maintenance, in 4-week steps.
- Ozempic (semaglutide) [2]: 4-week start at 0.25 mg, then 0.5 mg, with optional increases to 1.0 mg and 2.0 mg.
- Zepbound / Mounjaro (tirzepatide) [3][4]: 16-week titration from 2.5 mg to 15 mg maximum, increasing by 2.5 mg every 4 weeks.
- Foundayo (orforglipron) [5]: Daily oral tablet. 12-week titration from 3 mg to 36 mg maintenance.
Important warning
Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol. Do not change doses without medical guidance. If you are experiencing intolerable side effects at any dose level, contact your prescriber before your next scheduled increase — they may recommend staying at the current dose for additional weeks or reducing the dose.
What this planner does NOT do
- It does not provide medical advice or replace a conversation with your prescriber.
- It does not account for individual tolerance — the FDA labels include “as tolerated” language that your prescriber will apply to your situation.
- It does not generate prescriptions or medication orders.
- It does not track actual injection/pill dates — it shows the planned schedule for reference.
Important disclaimer
This planner is for educational purposes only and does not constitute medical advice or a prescription. The titration schedules shown are the standard FDA-label protocols. Your actual titration may differ based on your clinical response, tolerance, and your prescriber's judgment. Never adjust your medication dose without consulting your prescriber.
Related tools and research
- GLP-1 Dose Plotter — visualize your dose history over time
- GLP-1 Unit Converter — convert between mg, mL, and units
- GLP-1 Missed Dose Guide — what to do if you miss a dose during titration
- GLP-1 Weight Loss Calculator — week-by-week weight loss projections
- Switching between GLP-1 medications — what happens to titration when you switch drugs
- Semaglutide side effects: what to expect — the GI side effects that may affect titration pace
- Side-effect timeline tool — when each side effect peaks and resolves, by drug and week. Slower titration shifts the peak; this tool shows what you avoid.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1: Recommended Dosage. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- 2.Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
- 3.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
- 4.Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866Orig1s000lbl.pdf
- 5.Eli Lilly and Company. Foundayo (orforglipron) tablets — Prescribing Information. FDA / Drugs@FDA. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218226s000lbl.pdf